NS Partners Ltd Buys 11,910 Shares of Zoetis Inc. (NYSE:ZTS)

NS Partners Ltd raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 7.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 177,698 shares of the company's stock after acquiring an additional 11,910 shares during the period. Zoetis comprises 1.2% of NS Partners Ltd's portfolio, making the stock its 28th biggest position. NS Partners Ltd's holdings in Zoetis were worth $28,952,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services bought a new stake in Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC lifted its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its stake in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS stock traded up $3.09 during trading on Friday, reaching $170.34. 3,296,788 shares of the company's stock were exchanged, compared to its average volume of 3,274,650. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $76.28 billion, a PE ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The firm's fifty day moving average price is $166.72 and its 200-day moving average price is $176.74.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective on the stock. Finally, Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.